Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO.

Publication date: Jul 05, 2025

Diversity of the microbiota, which is essential for lower airway homeostasis, is greatly altered in acute respiratory distress syndrome (ARDS). Extracorporeal membrane oxygenation (ECMO) is the ultimate protective treatment for the lungs of patients with severe ARDS, but little is known about its effect on the lung microbiota of these patients. To evaluate the effect of ECMO on the lung microbiota of ARDS patients, we performed 16S rRNA and fungal ITS1 profiling and shotgun sequencing on bronchoalveolar lavage fluid (BALF) collected from ARDS patients due to COVID-19. BALF was collected from 13 patients, five of whom underwent ECMO. In all patients, Pseudomonas was the most abundant of the bacteria. The patients with ECMO had more Pseudomonas and more Klebsiella than those without ECMO. The most abundant fungi were unspecified fungi in the patients with ECMO and Emmia lacerata in the patients without ECMO. Alpha diversity of bacteria and fungi did not differ significantly between the two groups. Human betaherpesvirus 5 and human alphaherpesvirus 1 were predominant in all patients, with human betaherpesvirus 5 decreasing over time in the ECMO patients. The patients with ARDS due to COVID-19 receiving ECMO had a different lung microbiota than those not receiving ECMO.

Open Access PDF

Concepts Keywords
Bronchoalveolar Adult
Coronavirus Aged
Fungi ARDS
Homeostasis Bacteria
Severe Bronchoalveolar Lavage Fluid
COVID-19
COVID-19
ECMO
Extracorporeal Membrane Oxygenation
Female
Humans
Lung
Male
Microbiota
Microbiota
Middle Aged
Mycobiota
Respiratory Distress Syndrome
RNA, Ribosomal, 16S
RNA, Ribosomal, 16S
SARS-CoV-2
Virome

Semantics

Type Source Name
disease MESH coronavirus disease 2019
disease MESH acute respiratory distress syndrome
disease IDO bacteria
disease MESH Herpes simplex
disease MESH Dysbiosis
drug DRUGBANK Coenzyme M
disease IDO blood
drug DRUGBANK Oxygen
disease MESH lung injury
disease MESH hyperventilation
disease MESH emergency
disease IDO nucleic acid
drug DRUGBANK Clarithromycin
pathway REACTOME Release

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *